Louisiana State University, U.S.
Reports summarize research from Louisiana State University, U.S.
Published in Biotech Business Week, January 1st, 2007
This trend article about Louisiana State University, U.S., is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Patients with refractory solid tumor malignancies could be treated by the oral antimetabolite CS-682, administered once daily 5 days per week for 4 weeks followed by 2 weeks off drug.
According to recent research from the United States, "The development of nucleoside analogues has had a major impact on cancer therapy. CS-682 is a novel, orally administered nucleoside analogue with a unique mechanism of action."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Market Analysis
Compatibility of cell-based assays with high-throughput screening proving to be a key challenge - Market Analysis
Kalorama's research shows point-of-care diagnostics market to surpass $16 billion by 2010 - Market Analysis
Market for synthetic siRNA shows significant growth potential, market research shows - Market Analysis
Medical conferences ranked as best promotional channel for medical device companies - Market Analysis
Twin diseases of diabetes, obesity spur new drugs, methods of insulin delivery, report says - Asthma Therapy
Recent studies from Cambridge Antibody Technology add new data to asthma therapy - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
